AP NEWS

Global Huntington’s Disease Treatment Market Size, Share & Trends Analysis Report, 2018-2023 - ResearchAndMarkets.com

November 9, 2018

DUBLIN--(BUSINESS WIRE)--Nov 9, 2018--The “Huntington’s Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Therapy, Disease-modifying Therapy), By Major Markets, And Segment Forecasts, 2018 - 2023” report has been added to ResearchAndMarkets.com’s offering.

The global Huntington’s disease treatment market size is expected to be valued at USD 1.5 billion by 2023, registering a CAGR of 38.2% during the forecast period.

The market is largely driven by factors such as rapid uptake of disease-modifying therapies, increased adoption of novel therapeutics, and increase in R&D activities.

Huntington’s disease is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. Currently, only two symptom-alleviating therapies are specifically approved for this disorder: Xenazine and Austedo. Off-label medications are used extensively due to lack of approved alternatives.

The pipeline for Huntington’s disease is expected to witness rapid developments in the coming years as disease-modifying drugs transform the market landscape. Improved disease understanding has led to significant progress in the development of therapeutic approaches aimed at modifying specific changes linked to the causative mutation.

The potential role of RNA antisense technology and stem cell therapy are under active clinical investigation. Wave Life Sciences and Ionis Pharma’s antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Huntington’s Disease Treatment Market Overview

Chapter 5 Huntington’s Disease Treatment Market: Pipeline Intelligence

Chapter 6 Company Profiles

Valeant Pharmaceuticals Teva Pharmaceuticals Ionis Pharmaceuticals Wave Life Sciences Horizon Pharma Prana Biotech

For more information about this report visit https://www.researchandmarkets.com/research/gd4t49/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181109005253/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH GENETICS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/09/2018 07:33 AM/DISC: 11/09/2018 07:33 AM

http://www.businesswire.com/news/home/20181109005253/en

AP RADIO
Update hourly